DATE: November 18, 2026 at 08:00PM
SOURCE: PSYPOST.ORG
** Research quality varies widely from fantastic to small exploratory studies. Please check research methods when conclusions are very important to you. **
-------------------------------------------------
TITLE: GLP-1 drugs linked to reduced alcohol use and healthier eating in real-world study
Adults taking popular diabetes and weight-loss medications tended to cut back on alcohol and stick more closely to healthy diets over nearly a year of routine medical care, according to a new study published in Addictive Behaviors. Patients also reported feeling calm and peaceful more often, although broad measures of overall mental health and long-term physical activity did not show meaningful changes. The findings add real-world clinical evidence to growing scientific interest in how metabolic drugs might relate to everyday habits beyond blood sugar and weight control.
Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications that includes drugs such as semaglutide and dulaglutide, mimic a natural hormone released in the gut after eating. By binding to specialized proteins called receptors on cells in the pancreas, stomach, and brain, these drugs stimulate insulin release, slow digestion, and promote feelings of fullness. Doctors prescribe them widely to lower blood sugar in people with type 2 diabetes and to support weight loss in people with obesity.
Receptors for this hormone are not limited to regions that manage hunger and digestion. They also appear in the mesolimbic system, a network of deep brain structures that processes pleasure, motivation, and reward by releasing the chemical messenger dopamine. Animal experiments indicate that activating these receptors dampens dopamine surges triggered by addictive substances and reduces alcohol-seeking behavior.
Human studies have begun testing whether similar patterns emerge in medical patients. In people diagnosed with alcohol use disorder, a 2025 randomized clinical trial found that nine weeks of low-dose semaglutide lowered weekly alcohol cravings and reduced the amount of alcohol participants drank in a laboratory test compared with a placebo. Outside of controlled trials, a 2026 survey of a nationally representative U.S. sample indicated that roughly 44 percent of drinkers who started a GLP-1 medication recalled cutting back on alcohol during their first three months of treatment.
Whereas controlled clinical trials have focused largely on people seeking treatment for alcohol use disorder, most observational studies of everyday diabetes and obesity patients have relied on backward-looking medical record reviews or one-time surveys asking people to recall past habits. Less is known about how drinking, diet, exercise, and mood evolve together when tracked forward in time during routine metabolic care. Earlier work on the same patient dataset, reported in a 2026 study by several of the same authors, showed that 44 weeks of GLP-1 therapy improved body weight, blood sugar, physical functioning, and overall quality of life, while an overall mental health summary score did not show a statistically significant change.
To examine day-to-day habits and specific emotional states in closer detail, study lead author José Seijas-Amigo and his colleagues reanalyzed data from that Spanish clinical cohort, known as the SEVERAL study. Seijas-Amigo is head of the Clinical Trials Unit for Cardiology and Intensive Cardiac Care in the Department of Cardiology at the University Clinical Hospital of Santiago de Compostela, and is affiliated with the Foundation Health Research Institute of Santiago de Compostela and the University of Santiago de Compostela in Spain. Because the original project was designed primarily to evaluate metabolic health and drug safety rather than drinking or behavioral changes, the researchers framed this follow-up investigation as an exploratory, hypothesis-generating analysis.
“Addiction remains a major public health challenge, and pharmacological treatment options are still limited for many substance use disorders,” Seijas-Amigo told PsyPost. “This creates an important need to explore new therapeutic approaches, particularly medications that are already widely used for other conditions.”
“Growing evidence suggests that GLP-1 receptor agonists may influence not only metabolic regulation but also biological pathways involved in reward and addictive behaviors,” he added. “Although this was a post hoc observational analysis, we wanted to contribute real-world evidence to help determine whether these early signals deserve further investigation in dedicated clinical trials.”
The study followed 135 adults with both obesity and type 2 diabetes across multiple healthcare centers in Spain as they started or stepped up treatment with a GLP-1 medication as part of routine care. Participants had an average age of about 62 years, slightly more than half were men, and their average body mass index was 36.2, well above the threshold of 30 used to define obesity. Most patients had additional cardiovascular risk factors such as high blood pressure or abnormal cholesterol levels.
“I would like to highlight the collaborative work behind the SEVERAL project, particularly the contribution of primary care pharmacists, and the importance of multidisciplinary research connecting cardiology, metabolic medicine, and addiction specialists,” Seijas-Amigo noted. “This is also an approach we aim to promote through the Cardiology Clinical Trials Unit in Santiago de Compostela, which I lead.”
Doctors prescribed medications according to standard clinical judgment rather than random assignment. Roughly 35 percent of patients received dulaglutide, 31 percent took oral semaglutide, 30 percent used injectable semaglutide, and about 4 percent took liraglutide or exenatide. Over the 44-week study period, 43 percent of participants experienced an adverse drug reaction, with digestive issues such as nausea accounting for more than four-fifths of those cases. Among the 58 patients who experienced an adverse reaction, four stopped treatment permanently.
Clinicians assessed lifestyle habits at the start of the study and again at weeks 4, 12, and 44. Participants reported their typical daily alcohol intake in standard drink units, with one unit defined in Spain as 10 grams of pure alcohol, or roughly one small glass of wine or beer. Responses were grouped into three categories: zero to one drink per day, two drinks per day, or more than two drinks per day.
At those same visits, patients answered yes-or-no questions about whether they were following dietary recommendations and whether they were engaging in regular physical activity. At the beginning of treatment and at week 44, participants also completed two standardized health questionnaires that measure overall mental well-being, anxiety and depression, and specific emotional experiences over recent weeks, such as feeling calm and peaceful, feeling downhearted, or accomplishing less in daily tasks because of emotional difficulties.
Even before starting treatment, drinking levels in this group were generally low. Among the 130 patients with complete alcohol records, 87.7 percent already fell into the lowest category of zero to one standard drink per day, while 6.9 percent reported two drinks per day and 5.4 percent reported more than two.
Over 44 weeks of therapy, self-reported drinking shifted downward across those categories. By the final visit, 96.2 percent of participants were in the zero-to-one drink group, 3.8 percent reported two drinks per day, and none reported drinking more than two units daily.
Adherence to dietary advice also rose over the course of treatment. At the initial visit, 47.7 percent of participants reported following their recommended diet, a share that climbed to 66.7 percent at week 4 and settled at 63.2 percent at week 44. That improvement held steady when the researchers used statistical techniques to account for missing follow-up answers.
Physical activity followed a different trajectory. The proportion of patients reporting regular exercise climbed from 43.9 percent at the start to 56.1 percent at week 12, before slipping back to 50.4 percent by week 44. Comparing the start of the study with week 44, that long-term difference in physical activity was not statistically significant, a finding that remained unchanged after accounting for missing follow-up data.
“What I found particularly interesting was that not all lifestyle behaviors changed in the same way,” Seijas-Amigo observed. “We observed a shift toward lower categories of alcohol consumption and improved dietary adherence, but these changes were not accompanied by sustained improvements in physical activity.”
“This suggests that changes in health-related behaviors during GLP-1 receptor agonist therapy may be more complex than a general improvement in lifestyle,” he continued. “It raises interesting questions about whether different behavioral pathways are involved, although our study was not designed to investigate the underlying mechanisms.”
Broad assessments of mental health showed little overall movement over the 44 weeks. Changes in the general mental health summary score, which averaged 50.3 at baseline and 52.2 at week 44, were not statistically significant, and a separate rating of anxiety and depression problems also did not reach statistical significance.
When the researchers looked individually at specific mood questions in exploratory checks, one item stood out. The share of patients who reported feeling calm and peaceful all or most of the time rose from 51.9 percent at the beginning of treatment to 69.2 percent at week 44. Downward shifts in daily limitations from emotional problems were much more tentative: a drop in accomplishing less than desired sat right on the statistical borderline, and a reduction in working with less attention than usual fell slightly short and was not statistically significant.
Reports of feeling downhearted and blue, meanwhile, barely budged over the 44 weeks and were nowhere near statistically significant. Because the team tested multiple emotional items without statistical adjustments for repeated testing, the authors note that the increase in calmness could reflect a chance finding and should be read cautiously.
“I was also interested in the changes observed in certain aspects of emotional well-being, but these findings were exploratory and did not translate into statistically significant improvements in overall mental health measures,” Seijas-Amigo noted.
The downward shift in drinking aligns with a randomized placebo-controlled trial of adults with alcohol use disorder and obesity, which found that weekly semaglutide reduced heavy drinking days. That trial evaluated addiction patients rather than routine drinking categories in people with type 2 diabetes, yet both studies point toward lower alcohol intake during treatment. A similar pattern emerged in a health-registry study of patients with alcohol use disorder, which linked semaglutide and liraglutide to fewer alcohol-related hospitalizations rather than tracking self-reported drinking in people with diabetes and obesity.
In interpreting their results, the authors suggest several overlapping possibilities for why eating habits, drinking, and feelings of calmness shifted during therapy. Losing weight and gaining better control over blood sugar might boost how patients feel about their health and reinforce healthier routines. The researchers also propose that GLP-1 signaling in brain regions tied to appetite, stress, and reward could make rich foods and alcoholic beverages less enticing, though they caution that their study did not measure brain activity, cravings, or impulsivity directly.
Even with growing interest in how metabolic therapies might relate to behavior, Seijas-Amigo emphasized that everyday habits remain foundational. “For the general public, the most important message is that maintaining a healthy diet and avoiding alcohol consumption remain essential strategies for improving long-term health,” he said. “From a health perspective, drinking less is generally better, and not drinking alcohol is the safest option. Medications may eventually provide additional benefits, but they should never be viewed as a substitute for healthy lifestyle choices.”
There are a few things to keep in mind when interpreting these results. Because this was an observational study without an untreated comparison group, it cannot establish that the medications caused the behavioral changes. Regular checkups with healthcare providers, routine lifestyle advice, weight loss itself, or even digestive side effects like nausea could lead patients to eat differently and turn down alcoholic drinks.
In addition, nearly nine out of ten participants already drank one standard unit or less per day before starting the medication, leaving only 16 patients in the higher drinking brackets. Grouping zero drinks and one daily drink into a single category meant the questionnaire could not detect whether light drinkers quit altogether or cut back slightly, and no clinical screening tools for problem drinking were used. The findings also come from older adults managing obesity and type 2 diabetes in Spain, meaning they may not apply to younger people or to individuals seeking treatment for alcohol addiction.
Because of those baseline and measurement limits, Seijas-Amigo cautioned that “we cannot determine how much alcohol individuals actually reduced or whether these changes translated into meaningful long-term health benefits.”
“The changes we observed were encouraging, but their practical significance should be interpreted carefully,” he added. “I would consider these findings an interesting clinical signal rather than evidence of a large therapeutic effect. Their main value is helping identify questions that should be tested in larger, controlled clinical trials.”
“The most important misconception to avoid is that our study demonstrates that GLP-1 receptor agonists can treat alcohol addiction. It does not,” Seijas-Amigo stressed. “I believe these findings support further research, but they should not encourage people to use GLP-1 medications specifically to reduce alcohol consumption outside established medical indications. Promising biological hypotheses must ultimately be confirmed by well-designed randomized clinical trials.”
Future studies built specifically to track alcohol use and mental health will be needed to test whether these everyday behavioral shifts hold up under stricter conditions. Controlled trials that use detailed drinking logs, validated craving scales, and biological markers of alcohol intake could help clarify whether GLP-1 therapies directly alter reward-driven habits or work mainly through broader improvements in physical health.
“My main goal is to help move this field from promising observational findings to rigorous randomized clinical trials that can establish whether GLP-1-based therapies have a meaningful role in treating addictive disorders,” Seijas-Amigo explained. “I believe the priority now is to conduct well-designed clinical trials with clinically meaningful outcomes, such as sustained abstinence, relapse prevention, and long-term safety. These studies should be encouraged regardless of whether they are led by pharmaceutical companies, hospitals, or universities. Ultimately, what matters is generating robust, independent, and reproducible evidence that can determine whether these therapies offer real benefits to patients.”
Researchers are also beginning to look at related drugs such as tirzepatide, a newer diabetes and weight-loss medication that targets both GLP-1 receptors and a second gut hormone receptor involved in metabolism and appetite. Preclinical work, including a laboratory study in rodents that examined controlled drinking and brain reward signaling rather than self-reported alcohol intake in adult clinical patients, similarly linked tirzepatide to lower alcohol consumption, and scientists are exploring whether such medications might affect other addictive behaviors like smoking.
“In fact, I previously developed a research proposal to investigate tirzepatide as a potential aid for smoking cessation in patients with cardiovascular disease,” Seijas-Amigo added. “Although the project did not ultimately receive funding, it reflects my interest in exploring the intersection between cardiovascular health, addiction, and pharmacological innovation.”
“Finally, addiction remains highly stigmatized, sometimes even within healthcare,” Seijas-Amigo said. “We need greater recognition of addiction specialists and multidisciplinary treatment teams, better access to evidence-based pharmacological and psychological therapies, and more clinical research. People with substance use disorders deserve the same scientific attention and quality of care as patients with any other medical condition.”
The study, “Alcohol consumption, lifestyle behaviors, and emotional well-being during GLP-1 receptor agonist therapy: a post hoc analysis of the several study,” was authored by José Seijas-Amigo, Ángel Salgado-Barreira, Rosana Castelo-Dominguez, María Teresa Pérez-Álvarez, Belén Ponce-Piñón, Marlén Fernández-Silva, Marta Rodríguez-Barreiro, Mercedes Pereira-Pía, Jose Manuel Iglesias-Moreno, Mar Gago-García, Raquel Montáns-García, Agustina Fernandez-Perez, Dolores Fraga-Gayoso, Montse Fernandez-Montenegro, Beatriz Riveiro-Barciela, Natalia Rilla-Villar, Begoña Cardeso-Paredes, Marta Ribeiro-Ferreiro, Diego Rodriguez-Penas, Alberto Cordero, Moisés Rodríguez-Mañero, José R. González-Juanatey, and Several Investigators.
-------------------------------------------------
Private, vetted email list for mental health professionals: https://www.clinicians-exchange.org
Unofficial Psychology Today Xitter to toot feed at Psych Today Unofficial Bot @PTUnofficialBot
-------------------------------------------------
#psychology #counseling #socialwork #psychotherapy @psychotherapist @psychotherapists @psychology @socialpsych @socialwork @psychiatry #mentalhealth #psychiatry #healthcare #depression #psychotherapist #GLP1 #Semaglutide #WeightLoss #Diabetes #AlcoholResearch #HealthyEating #Nutrition #HealthResearch #AddictionResearch #ClinicalStudy